文献速递复苏、休克与脓毒症呼吸衰竭与机械通气

i-gel 声门上气道装置与气管插管在院外心脏骤停中的成本效果:AIRWAYS-2 随机对照试验结果

Cost-effectiveness of the i-gel supraglottic airway device compared to tracheal intubation during out-of-hospital cardiac arrest: Findings from the AIRWAYS-2 randomised controlled trial.
PubMed 文献 · Resuscitation · 2021-06-11
一句话结论AIRWAYS-2 成本效果分析显示,i-gel 与气管插管作为初始高级气道策略在成人非创伤性院外心脏骤停中6个月QALYs和费用差异很小,无成本效果差异。

AIRWAYS-2 整群随机对照试验比较了急救人员对成人非创伤性院外心脏骤停患者使用 i-gel 声门上气道装置与气管插管作为初始高级气道管理策略。本论文报告试验内成本效果分析,从英国国家卫生服务体系和个人社会服务视角、6个月时间范围,主要结局为 EQ-5D-5L 估算的质量调整生命年(QALYs),采用多水平线性回归模型处理急救人员整群效应。共9296例合格患者由1382名试验急救人员接诊并纳入(气管插管4410例,i-gel 4886例)。两组6个月平均QALYs均为0.03(i-gel 减气管插管差值 -0.0015,95%CI -0.0059 至 0.0028);人均总费用 i-gel 组 £3570、气管插管组 £3413(均差 £157,95%CI -£270 至 £583)。基于均差点估计,气管插管更有效且费用更低,但差异很小且结果不确定性大。结论认为两组QALYs和费用差异很小,i-gel 与气管插管作为成人非创伤性院外心脏骤停初始高级气道管理策略无成本效果差异。

要点

  • 9296例成人非创伤性院外心脏骤停患者由1382名急救人员接诊并纳入(气管插管4410例,i-gel 4886例)。
  • 两组6个月平均QALYs均为0.03,i-gel 减气管插管差值 -0.0015(95%CI -0.0059 至 0.0028)。
  • 人均总费用 i-gel 组 £3570 vs 气管插管组 £3413,均差 £157(95%CI -£270 至 £583)。
  • 基于均差点估计,气管插管更有效且费用更低,但差异很小且结果不确定性大。
  • 结论认为 i-gel 与气管插管作为初始高级气道管理策略无成本效果差异。

适用人群与场景

  • 成人非创伤性院外心脏骤停患者,由急救人员接诊并纳入 AIRWAYS-2 试验。

研究设计与关键结果

  • AIRWAYS-2 整群随机对照试验(ISRCTN08256118)的试验内成本效果分析,比较 i-gel 声门上气道装置与气管插管作为初始高级气道管理策略。
  • 共9296例合格患者由1382名试验急救人员接诊并纳入(气管插管4410例,i-gel 4886例)。
  • 6个月时间范围,从英国国家卫生服务体系和个人社会服务视角,主要结局为 EQ-5D-5L 估算的QALYs,采用多水平线性回归模型处理急救人员整群效应。
  • 两组6个月平均QALYs均为0.03,i-gel 减气管插管差值 -0.0015(95%CI -0.0059 至 0.0028)。
  • 人均总费用 i-gel 组 £3570 vs 气管插管组 £3413,均差 £157(95%CI -£270 至 £583)。
  • 基于均差点估计,气管插管更有效且费用更低;但差异很小且结果不确定性大。

证据类型、等级与局限

  • 证据类型:整群随机对照试验的成本效果分析。
  • 局限:差异很小且结果不确定性大。

对床旁实践的改变

  • 作者认为,i-gel 与气管插管作为成人非创伤性院外心脏骤停初始高级气道管理策略无成本效果差异。

指南或共识出处

  • AIRWAYS-2 整群随机对照试验(ISRCTN08256118)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Optimal airway management during out-of-hospital cardiac arrest (OHCA) is uncertain. Complications from tracheal intubation (TI) may be avoided with supraglottic airway (SGA) devices. The AIRWAYS-2 cluster randomised controlled trial (ISRCTN08256118) compared the i-gel SGA with TI as the initial advanced airway management (AAM) strategy by paramedics treating adults with non-traumatic OHCA. This paper reports the trial cost-effectiveness analysis.

METHODS: A within-trial cost-effectiveness analysis of the i-gel compared with TI was conducted, with a six-month time horizon, from the perspective of the UK National Health Service (NHS) and personal social services. The primary outcome measure was quality-adjusted life years (QALYs), estimated using the EQ-5D-5L questionnaire. Multilevel linear regression modelling was used to account for clustering by paramedic when combining costs and outcomes.

RESULTS: 9296 eligible patients were attended by 1382 trial paramedics and enrolled in the AIRWAYS-2 trial (4410 TI, 4886 i-gel). Mean QALYs to six months were 0.03 in both groups (i-gel minus TI difference -0.0015, 95% CI -0.0059 to 0.0028). Total costs per participant up to six months post-OHCA were £3570 and £3413 in the i-gel and TI groups respectively (mean difference £157, 95% CI -£270 to £583). Based on mean difference point estimates, TI was more effective and less costly than i-gel; however differences were small and there was great uncertainty around these results.

CONCLUSION: The small differences between groups in QALYs and costs shows no difference in the cost-effectiveness of the i-gel and TI when used as the initial AAM strategy in adults with non-traumatic OHCA.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Stokes EA, Lazaroo MJ, Clout M, et al. Cost-effectiveness of the i-gel supraglottic airway device compared to tracheal intubation during out-of-hospital cardiac arrest: Findings from the AIRWAYS-2 randomised controlled trial. Resuscitation. 2021. PMID: 34126133. doi:10.1016/j.resuscitation.2021.06.002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。